Thursday, February 13, 2014
An anonymous $275 million gift propels the Sanford-Burnham Medical Research Institute
more than halfway toward its funding goal for a newly announced 10-year drug
development plan that involves speeding the development of preclinical
therapies that it hopes to out-license.
Under Sanford-Burnham's 10-year plan, integrated disease
teams initially will function as informal working groups and will include basic
scientists, drug discovery experts and clinicians from Sanford-Burnham and its
Pharmas, present and future
In addition to promoting two-way communication between
the lab and clinic, the 10-year plan also will involve Sanford-Burnham using
its small molecule drug discovery platform to validate preclinical
candidates that could be licensed to pharmas, Vuori said.
Haas, M.J. SciBX 7(6);
doi:10.1038/scibx.2014.160 Published online Feb. 13, 2014
1. Haas, M.J. SciBX
2. Haas, M.J. SciBX
3. Haas, M.J. SciBX
4. Cain, C. SciBX 4(5);
5. Cain, C. SciBX 3(46);
AND INSTITUTIONS MENTIONED
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
National Institutes of Health, Bethesda, Md.
(NYSE:PFE), New York, N.Y.
Sanford-Burnham Medical Research Institute, La Jolla, Calif.
Sioux Falls, S.D.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
The Translational Research Institute for Metabolism and
Diabetes, Winter Park, Fla.
University of South Dakota, Vermillion, S.D.